Compared to Estimates, GoodRx (GDRX) Q2 Earnings: A Look at Key Metrics

GoodRx (GDRX) reported Q2 2025 revenue of $203.07 million, a 1.2% year-over-year increase, but missed the Zacks Consensus Estimate by 1.03%. EPS came in at $0.09, up from $0.08 year-over-year, yet fell short of the $0.10 consensus estimate by 10%. Segment performance was mixed, with Pharma manufacturer solutions revenue surging 32% year-over-year and exceeding estimates, while Prescription transactions and Subscription revenues declined and missed expectations. The stock has underperformed, returning -9.3% over the past month compared to the S&P 500's +0.5%.

Analysis

GoodRx Holdings, Inc. (GDRX) reported a mixed Q2 2025, characterized by modest top-line growth offset by significant weakness in its core business segments. While total revenue grew 1.2% year-over-year to $203.07 million and EPS increased to $0.09 from $0.08, both figures missed Wall Street consensus estimates, with revenue falling short by 1.03% and EPS by 10%. A deeper look at the key metrics reveals a concerning trend in the company's primary revenue streams. Revenue from Prescription transactions, the largest contributor, declined 2.5% YoY to $143.06 million, and Subscription revenue fell 7% YoY to $20.46 million; both segments also failed to meet analyst projections. The sole bright spot was the Pharma manufacturer solutions segment, which surged 32% year-over-year to $34.98 million, handily beating estimates. This bifurcation in performance highlights a potential strategic pivot but also underscores the challenges facing the consumer-facing parts of the business. The market has reacted negatively to these underlying weaknesses, with the stock returning -9.3% over the past month, starkly underperforming the S&P 500's +0.5% gain.

Key Decisions for Investors

• Investors should scrutinize the deteriorating performance in the core Prescription and Subscription segments, as their combined revenue decline currently overshadows the growth in the smaller Pharma solutions business.
• The 32% year-over-year growth in Pharma manufacturer solutions is a significant positive, and its future contribution should be monitored to assess if it can achieve the scale necessary to offset the erosion in other segments.
• Given the miss on both revenue and earnings per share and the stock's recent underperformance, a cautious stance is warranted until there is clear evidence of stabilization or a turnaround in the core consumer-facing revenue streams.